Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-04-2019 | Correspondence

De Novo JAK2 V617 F Positive AML: The Picture is Getting Clearer

Authors: Kanjaksha Ghosh, Kinjalka Ghosh

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2019

Excerpt

To: …

Tefferi A (2007) JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 13:366–371CrossRefPubMed

Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A (2018) JAK2 V617F-positiveacute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. Br J Haemtol 182:78–85CrossRef

Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F (2012) Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 119:4614–4618CrossRefPubMedPubMedCentral

Hidalgo-López JE, Kanagal-Shamanna R, Medeiros LJ, Estrov Z, Yin CC, Verstovsek S, Konoplev S, Jorgensen JL, Mohammad MM, Miranda RN, Zhao C, Lee J, Zuo Z, Bueso-Ramos CE (2017) Morphologic and molecular characteristics of De Novo AML With JAK2 V617F mutation. Nat Compr Cancer Netw J 15:790–796CrossRef

Swaminathan S, Madkaikar M, Ghosh K, Vundinti BR, Kerketta L, Gupta M (2010) Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with JAK2 V617F mutation. Eu J Haematol 84:180–182CrossRef

Ding W, Li D, Zhuang C, Wei P, Mou W, Zhang L, Liang H, Liu Y (2018) Essential thrombocythemia during treatment of acute myeloid leukemia ith JAK2V617F mutation: a casereport of a CARE-compliant article. Medicine (Baltimore) 97:e11331. https://doi.org/10.1097/MD.0000000000011331 CrossRef

Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH (2006) JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 20:971–978CrossRefPubMed

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. New Engl J Med 374:2209–2221CrossRefPubMed

Title: De Novo JAK2 V617 F Positive AML: The Picture is Getting Clearer
Authors: Kanjaksha Ghosh
Kinjalka Ghosh
Publication date: 01-04-2019
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 2/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-018-1041-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2019

Low Protein Z Level: A Thrombophilic Risk Biomarker for Acute Coronary Syndrome

Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia

Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation—A Single Centre Experience

Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking

Haemorrhagic Bulla: A Rare Presentation of Acute Lymphoblastic Leukemia

Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer